{"schema_version":"secwatch.filing_event.v1","accession":"0001798749-24-000036","form_type":"8-K","ticker":"JBIO","cik":"0001798749","company_name":"Jade Biosciences, Inc.","filed_at":"2024-06-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.165228+00:00","generated_at":"2026-06-01T00:45:07.576265+00:00","sec_items":["2.05"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Aerovate Therapeutics cuts 78% of workforce after halting AV-101 trial","bullets":["Reduction follows shutdown of Phase 2b/3 trial of AV-101 and long-term extension study.","First wave terminates 39 employees (78% of workforce); nearly all remaining staff to follow.","Estimated severance costs of $5.6 million, expected in Q3 and Q4 2024.","Severance contingent on separation agreement with general release of claims."],"urls":{"canonical":"https://secwatch.observer/filing/0001798749-24-000036","json":"https://secwatch.observer/filing/0001798749-24-000036.json","markdown":"https://secwatch.observer/filing/0001798749-24-000036.md","text":"https://secwatch.observer/filing/0001798749-24-000036.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1798749/000179874924000036/0001798749-24-000036-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1798749/000179874924000036/tmb-20240625x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T00:45:07.576265+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}